StockTipsArenaBeta

BUY Biocon Ltd — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYBiocon Ltd
Biocon share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))13 Jul 2026via NDTV Profit (Live)

Entry₹410.2Inferred
Target₹480
Total upside +17.02% (call closed)
Stop loss₹389-5.17% risk
At expiry₹43524 Jul 2026, 3:30 pm
Expired+6.05%
Follow Sachin Janardan Sarvade for new calls(13% target hit, 88 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 144 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 24 Jul 2026
7 supporting0 opposing
Supports the BUY call (7)

4 advisors have active short-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·24 Jul · today

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·23 Jul · today

Eternal shares may receive up to $650 million in inflows led by this positive trigger

NewsCnbc-Tv18·22 Jul · 2d ago

(opens in new tab)

Biocon's Malaysia facility gets European regulator approval for new drug product fill finish for insulin

NewsCnbc-Tv18·16 Jul · 1w ago

(opens in new tab)

Kiran Mazumdar-Shaw says Biocon succession is in place, bets on India's biopharma boom

NewsCnbc-Tv18·15 Jul · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome